Global Oral Solid Dosage Contract Manufacturing Market Size is valued at USD 35.6 Bn in 2024 and is predicted to reach USD 63.5 Bn by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034.
Oral Solid Dosage Contract Manufacturing are the complexity of new drug compounds will all contribute to the market's expansion. Because they are affordable, easy to produce, and convenient for patients, oral solids are the dosage forms that are most commonly used in the pharmaceutical industry. Oral solids can now attain even better levels of bioavailability while requiring less frequent medication administration because of developments in drug delivery technology, including the distribution of pharmaceuticals and sustained-release formulation. The most fundamental forms of solid dosage forms are tablets and capsules.
To improve patient compliance, businesses are already utilizing cutting-edge technologies to increase the bioavailability of dose forms. Contract manufacturers for oral solid dosage forms launch or improve new products. Increased investments in infrastructure development, plant expansions, and CDMO capabilities to offer fully integrated services will boost the contract development and manufacturing industry over the coming years.
The Oral Solid Dosage Contract Manufacturing market is categorized on the basis of product type, mechanism, and end-user. The product type segment includes tablets, capsules, powders, granules, and others (lozenges, gummies, pastilles, etc.). The mechanism segment includes immediate-release, delayed-release, and controlled-release. By end-user, the market is segmented into large-size companies, medium- & small-size companies, and others (startups & generic pharmaceutical companies).
The tablet and capsule category is expected to hold a major share of the global Oral Solid Dosage Contract Manufacturing market. This can be ascribed to the portability, simplicity in ingesting, good absorption, and medical adherence that various dose forms offer. Due to their expanded capabilities and enormous production capacities, established businesses (with over 10,000 employees) are also projected to hold over 50% of the current and future market in terms of company size.
The market has been divided into three types based on mechanisms: controlled-release, delayed-release, and immediate-release. In 2022, the controlled-release mechanism market category had a maximum revenue share. During the projected period, the segment is also anticipated to increase at the fastest rate. Drug developers can create medications that are kinder to patients while still being effective by altering the pace and/or location at which an API is released. Controlling the release of the API allows for a reduction in the number of dosages needed per day as well as the exclusion of variations in drug plasma levels, which often lead to fewer adverse effects.
With a significant CAGR over the projection period, Asia Pacific is anticipated to keep the quickest rate of growth in the region. Additionally, the region held the most important market share in 2021. With much lower prices, India and China are the APAC region's OSD CMO market leaders. Manufacturing of generic drugs is the second-largest source of revenue in the APAC area due to rising patent expiration rates.
CMOs are also working to achieve ISO accreditation in energy use, quality management, and environmental management. Additionally, while the quantity of warning letters has fallen in developed countries, it has risen in Asia Pacific, and transgressions of cGMP production standards have brought on most recalls. In addition, due to investments made by local businesses and increased FDA drug approval, North America is the second-most lucrative area.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 35.6 Bn |
|
Revenue forecast in 2034 |
USD 63.5 Bn |
|
Growth rate CAGR |
CAGR of 6.0% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product Type, Mechanism, And End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Catalent Inc; Lonza Group; Piramal Pharma Solutions; Aenova; Jubilant; Boehringer Ingelheim; AbbVie Contract Manufacturing; Patheon; Recipharm; Next Pharma AB; Siegfried AG; Corden Pharma. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Oral Solid Dosage Contract Manufacturing Market By Product Type Outlook-
Oral Solid Dosage Contract Manufacturing Market By Mechanism Outlook-
Oral Solid Dosage Contract Manufacturing Market By End-user Outlook-
Oral Solid Dosage Contract Manufacturing Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
